FDA Authorizes First Device to Continuously Monitor Glucose and Ketones

Why it matters locally: With West Virginia having a higher-than-average prevalence of diabetes, this new FDA authorization could provide critical continuous monitoring for many residents living with the disease, potentially improving health outcomes statewide.

The U.S. Food and Drug Administration has authorized the Libre Duo 10 Day Continuous Dual Glucose Ketone Monitoring System. This authorization marks the first time a wearable device has gained approval to continuously monitor both ketone levels and blood sugar. Individuals aged two years and older who live with diabetes can now use this system. The device provides continuous data on these two biomarkers.